In April 2025, researchers (Singh, 2025) reported they have developed a new mouse model lacking the BBS5 gene (BBS5/) to better understand Bardet-Biedl Syndrome (BBS), a rare genetic disorder marked by obesity, excessive hunger, learning difficulties, and metabolic dysfunction
No DAC lacks this albumin-binding component and acts for a shorter period
In the landmark SURMOUNT-1 trial, published in the New England Journal of Medicine, participants taking 15mg of tirzepatide lost an average of 20.9% of their body weight over 72 weeks
Results are gradual rather than instant
Common Side Effects Reference When to Adjust Protocol The vast majority of GHK-CU users experience no significant side effects
Contact a doctor promptly if mood changes, Depression, or suicidal thoughts develop during treatment